AFP and hepatocellular carcinoma: Based on these studies, the authors selected 13 compounds, while only four showed significant selective inhibition activity of both α-fetoprotein (AFP)+/CD133+ hepatocellular carcinoma (HCC) populations compared to the non-cancerous cell line [194].